Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (September 2015)
21 slides from Orthocell's investor presentation, Sep 23, 2015
Slide 1: Investor Presentation
For personal use only Investor Presentation September 2015 ASX: OCC Paul Anderson Managing Director
Slide 2: Disclaimer
Disclaimer For personal use only This presentation prepared by Orthocell Pty Ltd ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall ther
Slide 3: Company Overview
Company Overview For personal use only Orthocell Ltd is a regenerative medicine company • Founded in 2006, headquartered in developing cellular therapies and collagen scaffolds Australia, ASX listed August 2014 for the treatment of human tendons, ligaments and • Marketed products in Australia, Singa
Slide 4: Corporate Overview
Corporate Overview For personal use only Corporate Team ASX OCC CEO Paul Anderson • Verigen • Genzyme Share Price AU$0.67 (@ 17 Sep 2015) • Biomet Ordinary Shares on 82.5 million CSO Prof Ming Hao • Verigen issue Zheng • Genzyme • UWA Market Cap AU$55 million Executive Dr Stewart Washer • Cynata Cha
Slide 5: Positioned for growth
Positioned for growth For personal use only First tendon and ligament regeneration product in approved a majorin market a major with market 300 with significant patients treated globalinmarket a range potential of tendon applications Market for musculoskeletal conditions in US, EU and Japan targeted
Slide 6: Product overview
Product overview For personal use only Cell Therapies Product Development Stage Approval Status Current Applications Ortho-ATI™ Commercial Marketed in Australia Tennis elbow, achilles, Clinical in US/EU gluteal, patellar, rotator cuff Ortho-ACI™ Commercial Marketed in Australia Knee and Ankle Collag
Slide 7: Cellular Therapies
ortho cell lA ortho: cell Cellular Collagen Pipeline Therapies Scaffolds For personal use only tt
Slide 8: Ortho-ATI – Autologous Tenocyte Implantation
Ortho-ATI™ – Autologous Tenocyte Implantation For personal use only Ortho-ATI™ is a stem cell therapy to regenerate tendons and ligaments which: • uses each patient’s own stem cells to regenerate tendon tissue • enables healing of tendons, reduces pain and increases strength • greatly improves the p
Slide 9: Positioning Ortho-ATI
Positioning Ortho-ATI™ For personal use only Ortho-ATI™ is positioned as the preferred treatment for the repair and regeneration of damaged/injured tendons: Directly addresses the underlying pathology of Over 300 patients treated to tendinopathy (disease modifying) date. Demonstrated pathway to mark
Slide 10: Ortho-ATI clinical data
Ortho-ATI™ clinical data For personal use only Ortho-ATI™ tennis elbow study: • 20 patients that had failed all other treatments, with average 31 month symptoms on • Patients improved significantly with 1 patient proceeding to surgery • Data to 4.5 years recently published in American Journal Sports
Slide 11: Global expansion of Ortho-ATI
Global expansion of Ortho-ATI™ For personal use only Australian approval and marketing of Ortho-ATI™ de-risks global expansion: • 300 patients treated in Australia and parts of Asia • multiple tendons treated with no reported serious AE’s • sales tools and market entry strategy honed in pilot market
Slide 12: Ortho-ACI - Autologous Chondrocyte Implantation
Ortho-ACI™ - Autologous Chrondocyte Implantation For personal use only Ortho-ACI™ cell therapy to repair and regenerate articular cartilage: • uses each patient’s own cells to regenerate cartilage • applied to the knee and ankle • provides a functional and durable outcome • currently revenue generat
Slide 13: Global Ortho-ACI market is significant
Global Ortho-ACI™ market is significant For personal use only Market for cartilage repair is large and growing: • cartilage injuries affect people of all ages • approximately 900,000 people per annum develop cartilage disease in the US alone • 36% higher in athletes • cartilage injuries are found in
Slide 14: Collagen Scaffolds
ortho cell am ortho cell Cellular f Collagen Pipeline Therapies , Sca ffolds For personal use only
Slide 15: Collagen Scaffold Platform CelGro
Collagen Scaffold Platform CelGro™ For personal use only CelGro™ is a superior soft tissue regeneration technology: • natural source with consistent resorption • pure with no foreign DNA • high mechanical strength and pliability • superior cell compatibility Multiple applications: • tendon augmentat
Slide 16: Celgro clinical data – ear drum
Celgro™ clinical data – ear drum For personal use only Celgro™ ear drum (tympanic membrane) repair feasibility study: • patients with chronically ruptured ear drums, normal surgical repair failed • Extremely thin (80 micron) Celgro™ scaffold utilized to replace ear drum • Pilot stage complete – prep
Slide 17: Celgro clinical data - dental
Celgro™ clinical data - dental For personal use only Celgro™ dental soft tissue repair study: • 30 patient open label study requiring bone grafts to enable dental implants • Dentacol™ utilized for guided bone regeneration and to stop soft tissue ingrowth • Study underway with pleasing initial result
Slide 18: Celgro path to market
Celgro™ path to market For personal use only Pursuing direct and licence opportunities: • dental, orthopedic, ENT, gynaecology, general surgical • Bone Support AB partnership (December 2014) is first commercial collaboration and a strong external validation of the technology • significant opportunit
Slide 19: Pipeline
ernetel orthofen Cellular Collagen Therapies Scaffolds Pipeline
Slide 20: Next generation pipeline
Next generation pipeline For personal use only Strong product pipeline: Celgro • collagen powder for bone void fillers • guided nerve regeneration • braided ligament and ACL replacement Lab Grown Tendons • laboratory manufactured human tendon • replacement tendons for hands and other applications Gr
Slide 21: Positioned for growth
Positioned for growth For personal use only First tendon and ligament regeneration product in approved a majorin market a major with market 300 with significant patients treated globalinmarket a range potential of tendon applications Market for musculoskeletal conditions in US, EU and Japan targeted